{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:56:22Z","timestamp":1772477782320,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.clml.2021.07.004","type":"journal-article","created":{"date-parts":[[2021,7,18]],"date-time":"2021-07-18T17:32:34Z","timestamp":1626629554000},"page":"e810-e816","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections"],"prefix":"10.1016","volume":"21","author":[{"given":"Hajime","family":"Yasuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asako","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goh","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Miyake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.07.004_bib0001","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.clml.2020.08.017","article-title":"Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma","volume":"20","author":"Yasuda","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.07.004_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.clml.2021.07.004_bib0003","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1126\/science.abd3871","article-title":"Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans","volume":"370","author":"Mateus","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.clml.2021.07.004_bib0004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.16896","article-title":"Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature","volume":"190","author":"Tepasse","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102871","article-title":"Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma","volume":"59","author":"Karata\u015f","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.clml.2021.07.004_bib0006","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1111\/bjh.16981","article-title":"Convalescent plasma for persisting COVID-19 following therapeutic lymphocyte depletion: a report of rapid recovery","volume":"190","author":"Clark","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.004_bib0007","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1093\/infdis\/jiaa446","article-title":"Persistent COVID-19 in an Immunocompromised Patient Temporarily Responsive to Two Courses of Remdesivir Therapy","volume":"222","author":"Helleberg","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clml.2021.07.004_bib0008","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3389\/fonc.2020.01578","article-title":"Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab","volume":"10","author":"Kos","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2021.07.004_bib0009","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.927812","article-title":"A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma","volume":"21","author":"Moore","year":"2020","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.clml.2021.07.004_bib0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiaa666","article-title":"Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient","volume":"223","author":"Baang","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clml.2021.07.004_bib0011","article-title":"Sustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19","author":"Malsy","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clml.2021.07.004_bib0012","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.4269\/ajtmh.20-0678","article-title":"Case Report: a Patient with COVID-19 under Myelosuppression Induced by Chemotherapy","volume":"103","author":"Otsuka","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.clml.2021.07.004_bib0013","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jiac.2020.12.001","article-title":"Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient","volume":"27","author":"Nakajima","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.clml.2021.07.004_bib0014","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijid.2020.12.050","article-title":"Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir","volume":"104","author":"Camprub\u00ed","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.clml.2021.07.004_bib0015","article-title":"Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency","volume":"2","author":"Honjo","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.clml.2021.07.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153380","article-title":"Acute SARS-CoV-2 pneumonitis with cytotoxic CD8 positive T-lymphocytes: case report and review of the literature","volume":"220","author":"Puzyrenko","year":"2021","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.clml.2021.07.004_bib0017","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41375-021-01175-8","article-title":"Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection","volume":"35","author":"Reuken","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2021.07.004_bib0018","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.tracli.2021.04.004","article-title":"COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?","volume":"28","author":"Rnjak","year":"2021","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.clml.2021.07.004_bib0019","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1016\/j.clml.2021.02.009","article-title":"Delayed COVID-19 Respiratory Failure in Patients with Lymphoma on Rituximab-based Chemoimmunotherapy","volume":"21","author":"Hoffmann","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2021.07.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100739","article-title":"Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin\u2019s lymphoma: a case report","author":"Fujii","year":"2021","journal-title":"Curr Probl Cancer"},{"issue":"8","key":"10.1016\/j.clml.2021.07.004_bib0021","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/ajh.26209","article-title":"Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy","volume":"96","author":"Dul\u00e9ry","year":"2021","journal-title":"Am. J. Hematol"},{"key":"10.1016\/j.clml.2021.07.004_bib0022","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1182\/blood.2020008423","article-title":"Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19","volume":"136","author":"Hueso","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.07.004_bib0023","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/bjh.17266","article-title":"Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies","volume":"192","author":"Betrains","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.07.004_bib0024","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.jinf.2020.05.077","article-title":"Detection of SARS-CoV-2 antibodies using commercial assays and seroconversion patterns in hospitalized patients","volume":"81","author":"Tuaillon","year":"2020","journal-title":"J Infect"},{"key":"10.1016\/j.clml.2021.07.004_bib0025","first-page":"1","article-title":"Immune Thrombocytopenia Secondary to COVID-19: a Systematic Review","author":"Bhattacharjee","year":"2020","journal-title":"SN Compr Clin Med"},{"issue":"7","key":"10.1016\/j.clml.2021.07.004_bib0026","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/trf.16368","article-title":"Outcomes and management of immune thrombocytopenia secondary to COVID-19: cleveland clinic experience","volume":"61","author":"Kewan","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.clml.2021.07.004_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.201","article-title":"Persistent immune thrombocytopaenic purpura associated with SARS-CoV-2 infection","author":"Furukawa","year":"2021","journal-title":"eJHaem"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002731?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002731?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:08Z","timestamp":1761871088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021002731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S2152265021002731"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resolution of One-Year Persisting COVID-19 Pneumonia and Development of Immune Thrombocytopenia in a Follicular Lymphoma Patient With Preceding Rituximab Maintenance Therapy: A follow-up Report and Literature Review of Cases With Prolonged Infections","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}